ABCL
Abcellera Biologics Inc
NASDAQ: ABCL · HEALTHCARE · BIOTECHNOLOGY
$4.15
+8.64% today
Updated 2026-04-30
Market cap
$1.16B
P/E ratio
—
P/S ratio
15.41x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$2 – $7
Volume
4.1M
Abcellera Biologics Inc (ABCL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.56M | $2.69M | $22.69M | $244.58M | $277.36M | $-43.88M | $-108.56M | $-131.29M |
| Capital expenditures | $5.31M | $4.00M | $14.67M | $58.45M | $72.66M | $77.51M | $78.40M | $42.77M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $615000.00 | $890000.00 | $8.40M | $30.65M | $49.48M | $64.18M | $67.58M | $55.79M |
| Free cash flow | $-1.74M | $-1.30M | $8.02M | $186.13M | $204.70M | $-121.38M | $-186.95M | $-174.07M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | $14161.00 | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-91.55M | $-76.89M | — | — | — |